| 178.75 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 210.06 | 1-year : | 245.35 |
| Resists | First : | 179.85 | Second : | 210.06 |
| Pivot price | 178.75 | |||
| Supports | First : | 178.21 | Second : | 177.19 |
| MAs | MA(5) : | 178.75 | MA(20) : | 178.75 |
| MA(100) : | 170.29 |
MA(250) : | 144.27 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.28 |
| %K %D | K(14,3) : | 58.49 | D(3) : | 58.49 |
| RSI | RSI(14): 71.18 | |||
| 52-week | High : | 189.99 | Low : | 111.75 |
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Fri, 12 Apr 2024
Is Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Justified? - Yahoo Movies UK
Tue, 02 Nov 2021
Farallon Capital Opposes Terms of Merck's Acceleron Takeover - Bloomberg
Thu, 30 Sep 2021
Merck to Acquire Acceleron Pharma Inc. - Business Wire
Thu, 30 Sep 2021
Merck to buy Acceleron for about $11.5 bln in rare disease drug push - Reuters
Tue, 28 Sep 2021
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ - Merck & Co (NYSE:MRK), Bristol-Myers Squibb - Benzinga
Tue, 08 Jun 2021
Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 11.7 (%) |
| Held by Institutions | 91.4 (%) |
| Shares Short | 1,680 (K) |
| Shares Short P.Month | 1,980 (K) |
| EPS | -3.72 |
| EPS Est Next Qtrly | -0.64 |
| EPS Est This Year | -2.7 |
| EPS Est Next Year | -2.28 |
| Book Value (p.s.) | 12.56 |
| Profit Margin | -221.14 % |
| Operating Margin | -221.59 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -37.76 % |
| Qtrly Rev. Growth | -29.71 % |
| Gross Profit (p.s.) | -1.34 |
| Sales Per Share | 1.65 |
| EBITDA (p.s.) | -3.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -193 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -48.19 |
| PEG Ratio | 0 |
| Price to Book value | 14.23 |
| Price to Sales | 108.04 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|